Protealis Secures EUR 22 Million in Oversubscribed B-Round Funding to Propel Sustainable Plant Protein Seed Solutions

The proceeds from the B-Round funding will be instrumental in fueling Protealis' continued commercial development and expansion in key European markets

VIB spin-off Protealis, a leading innovator in seed solutions for sustainable plant protein based in Ghent, proudly announces the successful completion of its B-Round funding, raising a substantial EUR 22 million. Existing investors overwhelmingly reconfirmed their support for the company’s mission in an oversubscribed funding round, defying today’s challenging investment climate. The proceeds from the B-Round funding will be instrumental in fueling Protealis' continued commercial development and expansion in key European markets while growing its crop product portfolio and supporting technology platforms. These include high-tech innovations such as prediction of crop yield and quality, based on a combination of genetic fingerprinting and AI to further accelerate the introduction of new and better protein crop varieties to the market. This capital round implies a significant milestone for the company to continue its mission to sustainably transform the agricultural landscape. 

Protealis focuses on pioneering sustainable solutions for European farmers, addressing the growing demand for plant-based protein sources. The company's seed and seed breeding technology platforms not only enhance crop and protein level yields but also minimize the ecological impact of agriculture. By focusing on locally adapted plant legume crops that don’t require any additional mineral nitrogen fertilizers, Protealis aims to strengthen regional food systems and bringing novel opportunities to farmers, while contributing to global sustainability goals.

David Buckeridge, Chairman of the Board of Directors of Protealis, commented: “Succesfully securing EUR 22 million from our investors in today's challenging investment market shows that the rationale for Protealis and its mission for sustainable and high-performance legume crops as an essential part of our ​ future agriculture, is even bigger today than at our foundation. Looking at the rapid evolution of trends such as Regenerative Agriculture, there is no doubt that these systems will require significantly larger areas of legumes to be grown in Europe. This demands we breed for much higher field performance than is available for farmers today. Protealis is leading the industry in this area.”

In the past year, Protealis achieved significant milestones, including the successful launch of two proprietary soy seed varieties for colder European climates. The company also established a new speed breeding facility, now operational for over a year, to shorten the traditional breeding cycle by several years, and implemented a genomic mating platform to predict plant traits and enhance disease resistance when introducing new plant protein varieties. Positive yield trial results with yellow pea, the company’s upcoming legume crop and already a popular plant protein source for many food processors, further demonstrate Protealis’ commitment to keep innovating towards a more sustainable agriculture.

Benjamin Laga, CEO of Protealis, continued: “These positive results have resonated with investors ​ vwithin and outside of Protealis, positioning our company as a leader in the rapidly evolving landscape of plant-based protein solutions. With this funding, we are well-positioned to accelerate our commercial efforts and expand our footprint in the European market, ultimately contributing to a more sustainable and resilient agricultural future.”

The Series B fundraising was fully backed by the existing investor base, composed of V-Bio Ventures (BE), PMV (BE), VIB (BE), ILVO (BE), Agri Investment Fund (BE), Innovation Industries (NL), Korys Investments (BE), HFT Holding (NL), Thia Ventures (SG/BE), Gemma Frisius Fund (BE), Globachem Group (BE) and Estari Group (LU), underlining a solid trust in Protealis’ mission.

Protealis was launched as a spin-off from VIB and ILVO in April 2021 with EUR 6.0m VC funds, backed by an additional EUR 5

 

Share

Latest stories

Website preview
Researchers identify a key biological tipping point in Alzheimer’s disease
Leuven, 4 June 2026 – Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer’s disease pathology leads to dementia. Studying brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians, the team identified distinct cellular programs and immune-cell states associated with disease progression and resilience. Their findings, published in Nature Medicine, suggest that changes in microglia—the brain’s resident immune cells—could represent an important target for future Alzheimer’s therapies.
press.vib.be
Website preview
Prof. Diether Lambrechts (KU Leuven/VIB) receives the Francqui-Collen Prize 2026
Brussels, June 2, 2026 – Prof. Dr. Diether Lambrechts (KU Leuven/VIB) and Prof. Dr. Patrice Cani (UCLouvain) are the laureates of the Francqui-Collen Prize 2026, one of the highest scientific distinctions in Belgium. Today, they receive the award from the hands of King Philippe. Prof. Lambrechts is being honored for his groundbreaking genetic research into cancer treatments, while Prof. Cani is recognized for his discoveries regarding the impact of gut bacteria on lifestyle-related diseases.
press.vib.be
Website preview
Comprehensive atlas maps dendritic cells across cancers
Brussels, 01 June 2026 — Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells. By integrating data from 14 mouse tumor models and 10 human cancer types, the study provides a detailed, cross-species view of how these key immune cells are organized and altered in cancer. This work, which appeared in Nature Communications, can guide the development of next-generation therapies.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be